Novel facts about FAK: new connections to drug resistance?
Affiliations of authors: Center for Cancer Research (CMA) and Clinical Investigations Branch, Cancer Therapy Evaluation Program (ECK), National Cancer Institute, Bethesda, MD.
Christina M
CM
Annunziata
Elise C
EC
Kohn
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism*; D006801:Humans; D009930:Organic Chemicals / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D017239:Paclitaxel / Q000494:pharmacology*; D011719:Pyrazines; D013449:Sulfonamides; D051840:Y-Box-Binding Protein 1 / Q000378:metabolism*
D001549:Benzamides; D009930:Organic Chemicals; D011719:Pyrazines; D013449:Sulfonamides; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human; C584510:defactinib; D051417:Focal Adhesion Kinase 1; C496050:PTK2 protein, human; D017239:Paclitaxel